Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study
Immunity, Inflammation and Disease · 2025
DOI: 10.1002/iid3.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Fengjuan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Latent Tuberculosis, Rheumatic Diseases, Tuberculosis. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The study was supported by the National Natural Science Foundation of China (Grant No. 81972026 to J.L.) and the National Key Research and Development Program….
Abstract (Originalsprache)
Background
In rheumatism patients, the immune system erroneously attacks the body′s own tissues. This impairs the body′s defense against external pathogens and is a contributing factor to the occurrence of tuberculosis infection. The primary objective of this investigation was to examine the risk factors for the progression from latent tuberculosis infection (LTBI) to active tuberculosis (ATB) in patients with rheumatic diseases (RD).
Methods
RD cover a wide range of disorders affecting the skeletal system, joints, and adjacent soft tissues. When the human body is infected by Mycobacterium tuberculosis , the condition is classified as either LTBI or ATB, depending on the presence or absence of typical clinical symptoms. A retrospective study was conducted at the Xijing Hospital of the Fourth Military Medical University. Specifically, the Laboratory Information System was used to investigate patients diagnosed with RD from January 2012 to October 2022.
Results
The study included a total of 32,235 individuals diagnosed with rheumatism, of whom only 18.60% were screened for LTBI. The overall incidence of LTBI was 25.33%. Among the 629 RD inpatients with LTBI, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) accounted for half, and 56.44% received glucocorticoid (GC) therapy. Risk‐factor assessment for ATB was conducted in 247 cases. A GC dose of 20 mg/day or more was an independent risk factor for LTBI activation (odds ratio = 3.59, 95% CI: 1.26–10.29, p = 0.017).
Conclusion
In China, RD patients have a relatively high risk of LTBI. In clinical practice, LTBI screening should be routinely performed for RD patients before initiating GC therapy at a dose of ≥ 20 mg/day. For patients with SLE and RA undergoing continuous GC treatment, close monitoring is essential. In addition, clinicians should enhance the diagnostic pathways and treatment management for these patients to prevent the occurrence of ATB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
ORCID-Profile: Fengjuan Wang, Jiayun Liu
Förderung
- The study was supported by the National Natural Science Foundation of China (Grant No. 81972026 to J.L.) and the National Key Research and Development Program…
Zitieren
APA
Wang, F., Zhou, L., Hao, X., & Liu, J. (2025). Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70270
Vancouver
Wang F, Zhou L, Hao X, Liu J. Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70270
BibTeX
@article{Wang2025,
author = {Wang, Fengjuan and Zhou, Lei and Hao, Xiaoyan and Liu, Jiayun},
title = {Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study},
journal = {Immunity, Inflammation and Disease},
year = {2025},
doi = {10.1002/iid3.70270}
}
EUVIMED